Coulter Partners successfully led a search for Neumirna Therapeutics and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer.
The project will focus on advancing MDX-201, an innovative ADC that links a cytotoxic payload with a first-in-class monoclonal antibody (MDX-124) that targets annexin-A1.
Stevenage Bioscience Catalyst is deeply saddened to share the news that our CEO, Dr Sally Ann Forsyth OBE, passed away at home on Saturday 2 May after a long battle with illness.
